These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

639 related items for PubMed ID: 26382580

  • 1. Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial.
    Eskesen D, Jespersen L, Michelsen B, Whorwell PJ, Müller-Lissner S, Morberg CM.
    Br J Nutr; 2015 Nov 28; 114(10):1638-46. PubMed ID: 26382580
    [Abstract] [Full Text] [Related]

  • 2. Dose-response study of probiotic bacteria Bifidobacterium animalis subsp lactis BB-12 and Lactobacillus paracasei subsp paracasei CRL-341 in healthy young adults.
    Larsen CN, Nielsen S, Kaestel P, Brockmann E, Bennedsen M, Christensen HR, Eskesen DC, Jacobsen BL, Michaelsen KF.
    Eur J Clin Nutr; 2006 Nov 28; 60(11):1284-93. PubMed ID: 16721394
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of the immune benefits of two probiotic strains Bifidobacterium animalis ssp. lactis, BB-12® and Lactobacillus paracasei ssp. paracasei, L. casei 431® in an influenza vaccination model: a randomised, double-blind, placebo-controlled study.
    Rizzardini G, Eskesen D, Calder PC, Capetti A, Jespersen L, Clerici M.
    Br J Nutr; 2012 Mar 28; 107(6):876-84. PubMed ID: 21899798
    [Abstract] [Full Text] [Related]

  • 4. Xylo-oligosaccharides alone or in synbiotic combination with Bifidobacterium animalis subsp. lactis induce bifidogenesis and modulate markers of immune function in healthy adults: a double-blind, placebo-controlled, randomised, factorial cross-over study.
    Childs CE, Röytiö H, Alhoniemi E, Fekete AA, Forssten SD, Hudjec N, Lim YN, Steger CJ, Yaqoob P, Tuohy KM, Rastall RA, Ouwehand AC, Gibson GR.
    Br J Nutr; 2014 Jun 14; 111(11):1945-56. PubMed ID: 24661576
    [Abstract] [Full Text] [Related]

  • 5. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome.
    Drouault-Holowacz S, Bieuvelet S, Burckel A, Cazaubiel M, Dray X, Marteau P.
    Gastroenterol Clin Biol; 2008 Feb 14; 32(2):147-52. PubMed ID: 18387426
    [Abstract] [Full Text] [Related]

  • 6. Probiotic treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial with Lactobacillus acidophilus and Bifidobacterium animalis subsp. Lactis.
    Wildt S, Munck LK, Vinter-Jensen L, Hanse BF, Nordgaard-Lassen I, Christensen S, Avnstroem S, Rasmussen SN, Rumessen JJ.
    Inflamm Bowel Dis; 2006 May 14; 12(5):395-401. PubMed ID: 16670529
    [Abstract] [Full Text] [Related]

  • 7. Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Benefit of the Probiotic Bifidobacterium infantis 35624 in Non-Patients With Symptoms of Abdominal Discomfort and Bloating.
    Ringel-Kulka T, McRorie J, Ringel Y.
    Am J Gastroenterol; 2017 Jan 14; 112(1):145-151. PubMed ID: 27845337
    [Abstract] [Full Text] [Related]

  • 8. Safety of Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12-supplemented yogurt in healthy adults on antibiotics: a phase I safety study.
    Merenstein DJ, Tan TP, Molokin A, Smith KH, Roberts RF, Shara NM, Mete M, Sanders ME, Solano-Aguilar G.
    Gut Microbes; 2015 Jan 14; 6(1):66-77. PubMed ID: 25569274
    [Abstract] [Full Text] [Related]

  • 9. Probiotic supplementation for respiratory and gastrointestinal illness symptoms in healthy physically active individuals.
    West NP, Horn PL, Pyne DB, Gebski VJ, Lahtinen SJ, Fricker PA, Cripps AW.
    Clin Nutr; 2014 Aug 14; 33(4):581-7. PubMed ID: 24268677
    [Abstract] [Full Text] [Related]

  • 10. The therapeutic efficacy of Bifidobacterium animalis subsp. lactis BB-12® in infant colic: A randomised, double blind, placebo-controlled trial.
    Nocerino R, De Filippis F, Cecere G, Marino A, Micillo M, Di Scala C, de Caro C, Calignano A, Bruno C, Paparo L, Iannicelli AM, Cosenza L, Maddalena Y, Della Gatta G, Coppola S, Carucci L, Ercolini D, Berni Canani R.
    Aliment Pharmacol Ther; 2020 Jan 14; 51(1):110-120. PubMed ID: 31797399
    [Abstract] [Full Text] [Related]

  • 11. Effects of synbiotic fermented milk containing Lactobacillus acidophilus La-5 and Bifidobacterium animalis ssp. lactis BB-12 on the fecal microbiota of adults with irritable bowel syndrome: A randomized double-blind, placebo-controlled trial.
    Bogovič Matijašić B, Obermajer T, Lipoglavšek L, Sernel T, Locatelli I, Kos M, Šmid A, Rogelj I.
    J Dairy Sci; 2016 Jul 14; 99(7):5008-5021. PubMed ID: 27157575
    [Abstract] [Full Text] [Related]

  • 12. Fermented milk containing Bifidobacterium lactis DN-173 010 improves gastrointestinal well-being and digestive symptoms in women reporting minor digestive symptoms: a randomised, double-blind, parallel, controlled study.
    Guyonnet D, Schlumberger A, Mhamdi L, Jakob S, Chassany O.
    Br J Nutr; 2009 Dec 14; 102(11):1654-62. PubMed ID: 19622191
    [Abstract] [Full Text] [Related]

  • 13. Impact of Bifidobacterium animalis subsp. lactis BB-12 and, Lactobacillus acidophilus LA-5-containing yoghurt, on fecal bacterial counts of healthy adults.
    Savard P, Lamarche B, Paradis ME, Thiboutot H, Laurin É, Roy D.
    Int J Food Microbiol; 2011 Sep 01; 149(1):50-7. PubMed ID: 21296446
    [Abstract] [Full Text] [Related]

  • 14. Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial.
    Andresen V, Gschossmann J, Layer P.
    Lancet Gastroenterol Hepatol; 2020 Jul 01; 5(7):658-666. PubMed ID: 32277872
    [Abstract] [Full Text] [Related]

  • 15. Effects of 28-day Bifidobacterium animalis subsp. lactis HN019 supplementation on colonic transit time and gastrointestinal symptoms in adults with functional constipation: A double-blind, randomized, placebo-controlled, and dose-ranging trial.
    Ibarra A, Latreille-Barbier M, Donazzolo Y, Pelletier X, Ouwehand AC.
    Gut Microbes; 2018 Jul 01; 9(3):236-251. PubMed ID: 29227175
    [Abstract] [Full Text] [Related]

  • 16. Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial.
    Martoni CJ, Srivastava S, Leyer GJ.
    Nutrients; 2020 Jan 30; 12(2):. PubMed ID: 32019158
    [Abstract] [Full Text] [Related]

  • 17. Effect of combined bifidobacteria supplementation and resistance training on cognitive function, body composition and bowel habits of healthy elderly subjects.
    Inoue T, Kobayashi Y, Mori N, Sakagawa M, Xiao JZ, Moritani T, Sakane N, Nagai N.
    Benef Microbes; 2018 Dec 07; 9(6):843-853. PubMed ID: 30198326
    [Abstract] [Full Text] [Related]

  • 18. Eight-Week Supplementation With Bifidobacterium lactis HN019 and Functional Constipation: A Randomized Clinical Trial.
    Cheng J, Gao C, Ala-Jaakkola R, Forssten SD, Saarinen M, Hibberd A, Ouwehand AC, Ibarra A, Li D, Nordlund A, Wang Y, Shen X, Peng H, Wan X, Meng X.
    JAMA Netw Open; 2024 Oct 01; 7(10):e2436888. PubMed ID: 39356506
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome.
    Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O'Mahony L, Kiely B, Shanahan F, Quigley EM.
    Am J Gastroenterol; 2006 Jul 01; 101(7):1581-90. PubMed ID: 16863564
    [Abstract] [Full Text] [Related]

  • 20. The efficacy of Bifidobacterium quadruple viable tablet in the treatment of diarrhea predominant irritable bowel syndrome: protocol for a randomized, double-blind, placebo-controlled, multicenter trial.
    Bai T, Zeng H, Long Y, Li X, Sun X, Lan Y, Gao L, Zhang L, Feng Z, Hou X.
    Trials; 2020 Jun 30; 21(1):597. PubMed ID: 32605578
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.